A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9
Phase 1
Recruiting
- Conditions
- Influenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2022-500706-18-01
- Lead Sponsor
- Oslo University Hospital Hf
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method